P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy
Human Pathology,
Borys D et al. – Immunohistochemical expression of P16 significantly correlates with chemotherapy response in osteosarcoma. P16 expression may be a useful biomarker to guide treatment selection.



